Guggenheim Maintains Veracyte Buy Rating, Cuts Target Price to $35
Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Veracyte, Inc. while lowering the price target to $35.
Stocks · News reference
Piper Sandler has maintained a Buy rating on Veracyte, Inc. while significantly reducing its price target for the company's stock.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Veracyte, Inc. while lowering the price target to $35.
Analyst Mason Carrico of Stephens & Co. has maintained an 'Overweight' (Buy) rating on Veracyte, Inc. while adjusting the price target.
UBS has revised its price target for Veracyte, Inc. to $35 from the previous $65 while maintaining a Buy rating on the stock.